A recent article featured in Orthopedics This Week discussed exciting developments in the field of regenerative orthopedics, presented at the New York Stem Cell Summit in February. A clinical trial conducted out of Shanghai’s Renji Hospital analyzed the effects of fat-derived Mesenchymal Stem Cells on knee osteoarthritis.
Not only did the study reveal no adverse side effects, but patients experienced decreased knee pain, better mobility, and longer walking distance. In addition, researchers observed increases in cartilage thickness, assessed via MRI, as soon as 3 months post-treatment, while some patients also illustrated a decrease in the number of bone lesions. Three of the patients confirmed similar findings at 6 month follow-up. Currently, 6 month follow-up visits are still being completed for all of the patients in the trial.
Although the clinical trial is still in the preliminary phases of testing, the initial conclusion of the study is that “ReJoin cell therapy for knee osteoarthritis patients is safe”. With the prevalence of osteoarthritis on the rise, and ineffective methods of drug-based therapy, the application of fat-derived Mesenchymal Stem Cells for Osteoarthritis could prove to be extremely beneficial for future treatment and reversal of the disease. This study adds further validity to the regenerative potential of Orthobiologics and their potential to improve quality of life in patients suffering from Osteoarthritis.
Stay connected on Twitter and Facebook for more up to date research and health articles!
